Mersana Therapeutics to Present at Jefferies London Healthcare Conference
November 08 2022 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that members of
management will present at the Jefferies London Healthcare
Conference on Tuesday, November 15, 2022, at 3:50 p.m. GMT (10:50
a.m. ET).
A live webcast of the presentation will be available on the
Investors & Media section of Mersana’s website at
www.mersana.com. An archived replay will be available for
approximately 90 days following the event.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to rapidly develop
novel ADCs with optimal efficacy, safety and tolerability to
meaningfully improve the lives of people fighting cancer. Mersana’s
lead product candidate, upifitamab rilsodotin (UpRi), is a
Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a
single-arm registrational trial in patients with platinum-resistant
ovarian cancer; UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi
in combination with other ovarian cancer therapies; and UP-NEXT, a
Phase 3 clinical trial of UpRi as monotherapy maintenance following
treatment with platinum doublets in recurrent platinum-sensitive
ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen
ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a
novel epitope of human epidermal growth factor receptor 2 (HER2),
in addition to other earlier-stage assets. In addition, multiple
partners are using Mersana’s platforms to advance their ADC
pipelines. Mersana Therapeutics was named among the 2021 Top Places
to Work in Massachusetts by The Boston Globe. Mersana routinely
posts information that may be useful to investors on the “Investors
& Media” section of its website at www.mersana.com.
Contact:Jason Fredette
617-498-0020jason.fredette@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024